{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:46:33Z","timestamp":1790531193633,"version":"4.1.0"},"reference-count":131,"publisher":"Informa UK Limited","issue":"12","funder":[{"DOI":"10.13039\/100001146","name":"Greenwall Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001146","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011641","name":"Muscular Dystrophy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011641","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Bioethics"],"published-print":{"date-parts":[[2021,12,2]]},"DOI":"10.1080\/15265161.2021.1974975","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T02:16:38Z","timestamp":1634782598000},"page":"4-19","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?"],"prefix":"10.1080","volume":"21","author":[{"given":"Holly Fernandez","family":"Lynch","sequence":"first","affiliation":[{"name":"University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Caplan","sequence":"additional","affiliation":[{"name":"NYU Langone Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Furlong","sequence":"additional","affiliation":[{"name":"Parent Project Muscular Dystrophy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bateman-House","sequence":"additional","affiliation":[{"name":"NYU Langone Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2110468"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4984"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3284"},{"key":"CIT0004","unstructured":"Austin, C. P. 2021. COVID\u2019s all-hands-on-deck approach should be standard for rare diseases. The Hill, March 18, 2021. https:\/\/thehill.com\/opinion\/healthcare\/543461-covids-all-hands-on-deck-approach-should-be-standard-for-rare-diseases."},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01650-6"},{"key":"CIT0006","unstructured":"Baker, S., and C. Koons. 2020. Inside operation warp speed\u2019s $18 billion sprint for a vaccine. Bloomberg Businessweek, October 29, 2020. https:\/\/www.bloomberg.com\/news\/features\/2020-10-29\/inside-operation-warp-speed-s-18-billion-sprint-for-a-vaccine."},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-03626-1"},{"key":"CIT0008","unstructured":"Bard, J. 2020. Why the military can use emergency powers to treat service members with trial COVID-19 drugs. The Conversation. May 11, 2020. http:\/\/theconversation.com\/why-the-military-can-use-emergency-powers-to-treat-service-members-with-trial-covid-19-drugs-135876."},{"key":"CIT0009","unstructured":"Bateman-House, A., Gustafson, S., Masserelli, J., et\u00a0al. 2021. Clinical use of unproven interventions outside of research during a public health emergency: Ethical issues and policy guidance. Report to the World Health Organization, available upon request."},{"key":"CIT0010","unstructured":"Belluck, P., and R. Robbins. 2021. F.D.A. approves Alzheimer\u2019s drug despite fierce debate over whether it works. New York Times, June 7, 2021. https:\/\/www.nytimes.com\/2021\/06\/07\/health\/aduhelm-fda-alzheimers-drug.html."},{"key":"CIT0011","unstructured":"Bowen, A. 2021. Ex-Obama staffer says COVID-19 vaccines show ALS cure is possible. Chicago Tribune, January 30, 2021. https:\/\/www.chicagotribune.com\/coronavirus\/ct-life-covid-brian-wallach-sandra-abrevaya-als-cure-tt-20210130-5ro4heypsbgfff7o6bk6zdliiu-story.html."},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.06.003"},{"key":"CIT0013","volume-title":"No magic bullet: A social history of venereal disease in the United States since 1880","author":"Brandt A. M.","year":"1987"},{"key":"CIT0014","unstructured":"Branswell, H., M. Herper, L. Facher, E. Silverman, and N. Florko. 2020. Operation warp speed pledged to do the impossible. How far has it come? STAT News, September 8, 2020. https:\/\/www.statnews.com\/2020\/09\/08\/operation-warp-speed-promised-to-do-the-impossible-how-far-has-it-come\/."},{"key":"CIT0015","unstructured":"Brice\u00f1o, C. 2021. Operation warp speed should inspire a similar effort for rare diseases, December 22, 2021. https:\/\/huntingtonsdiseasenews.com\/2020\/12\/22\/operation-warp-speed-should-inspire-rare-disease-effort\/."},{"key":"CIT0016","unstructured":"Bright, R. 2020. U.S. office of special counsel complaint & disclosure form. https:\/\/context-cdn.washingtonpost.com\/notes\/prod\/default\/documents\/6bfde4d6-4c3d-4671-8eeb-6b3d39e47c03\/note\/26f73d7a-d060-4c25-af4c-a58a167ee2c7.#page=1&pagemode=none&toolbar=1&statusbar=1."},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00037-3"},{"key":"CIT0018","unstructured":"Caforio, G. 2020. Bristol Myers Squibb CEO: Why the COVID-19 pandemic has me optimistic about the future of medical research. Fortune, June 9, 2020. https:\/\/fortune.com\/2020\/06\/09\/coronavirus-research-collaboration-treatment-vaccine\/."},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146391"},{"key":"CIT0020","author":"Cohen J.","year":"2020","journal-title":"Science"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30452-X"},{"key":"CIT0024","unstructured":"Edney, A., and J. Lauerman. 2020. Get ready for \u2018where\u2019s my warp speed? Bloomberg, December 28, 2020. https:\/\/www.bloomberg.com\/news\/newsletters\/2020-12-28\/get-ready-for-where-s-my-warp-speed."},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190426"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb2005114"},{"key":"CIT0027","unstructured":"Eschner, K. 2021. After 600 emergency use authorizations for COVID, experts worry the FDA has gone too far. Fortune, June 7, 2021. https:\/\/fortune.com\/2021\/06\/07\/covid-emergency-use-authorizations-fda-euas-therapies-drugs-medicines-pandemic\/."},{"key":"CIT0028","unstructured":"EveryLife Foundation for Rare Diseases. 2021. The national economic burden of rare disease study. https:\/\/everylifefoundation.org\/wp-content\/uploads\/2021\/02\/The_National_Economic_Burden_of_Rare_Disease_Study_Summary_Report_February_2021.pdf."},{"key":"CIT0029","unstructured":"Facher, L. 2021. Biden pitches a new health agency to help \u2018end cancer as we know it. STAT. April 28, 2021. https:\/\/www.statnews.com\/2021\/04\/28\/biden-pitches-new-health-agency-to-end-cancer\/."},{"key":"CIT0030","unstructured":"Feldman, R. 2019. Why the cancer \u2018moonshot\u2019 has been so disappointing. Washington Post, September 24, 2019. https:\/\/www.washingtonpost.com\/outlook\/2019\/09\/24\/why-cancer-moonshot-has-been-so-disappointing\/."},{"key":"CIT0031","unstructured":"Florko, N. 2021. Advocates blast the FDA for not moving as fast on ALS as on Alzheimer\u2019s. STAT, June 11, 2021. https:\/\/www.statnews.com\/2021\/06\/11\/advocates-blast-fda-for-not-fast-als-alzheimers\/."},{"issue":"1","key":"CIT0032","first-page":"85","volume":"11","author":"Folkers K. M.","year":"2020","journal-title":"Wake Forest Journal of Law & Policy"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2016-103680"},{"key":"CIT0034","unstructured":"Gilead. 2020. Gilead\u2019s investigational antiviral remdesivir receives U.S. Food and Drug Administration emergency use authorization for the treatment of COVID-19. May 1, 2020. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/5\/gileads-investigational-antiviral-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-covid19."},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6942e1"},{"key":"CIT0036","unstructured":"Green, P. 2020. I\u2019m happy COVID-19 patients can access experimental drugs. Too bad those of us with ALS can\u2019t. The Arizona Republic, May 21, 2020. https:\/\/www.azcentral.com\/story\/opinion\/op-ed\/2020\/05\/21\/covid-19-patients-have-experimental-drugs-als-patients-like-me-dont\/5226684002\/."},{"key":"CIT0037","unstructured":"Guillot, J. 2021. The FDA needs to apply its Covid-19 flexibility to pediatric cancer. STAT, January 6, 2021. https:\/\/www.statnews.com\/2021\/01\/06\/fda-apply-covid-19-flexibility-to-pediatric-cancer\/."},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002191"},{"key":"CIT0039","unstructured":"Herper, M., and E. Riglin. 2020. Data show panic, disorganization dominate the study of Covid-19 drugs. STAT, July 6, 2020. https:\/\/www.statnews.com\/2020\/07\/06\/data-show-panic-and-disorganization-dominate-the-study-of-covid-19-drugs\/."},{"key":"CIT0040","unstructured":"Herper, M. 2021. By approving Biogen\u2019s alzheimer\u2019s drug, the FDA is shifting its rules. That is a giant risk. STAT, June 7, 2021. https:\/\/www.statnews.com\/2021\/06\/07\/by-approving-biogen-alzheimers-drug-fda-is-shifting-its-rules-that-is-a-giant-risk\/."},{"key":"CIT0041","unstructured":"Hiltzik, M. 2020. Column: The false, lethal promise of \u2018warp speed\u2019 science. Los Angeles Times, August 25, 2020. https:\/\/www.latimes.com\/business\/story\/2020-08-25\/false-promise-warp-speed-science."},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7"},{"key":"CIT0043","unstructured":"Human Genome Research Institute. n.d. The human genome project. https:\/\/www.genome.gov\/human-genome-project."},{"key":"CIT0044","unstructured":"Infectious Diseases Society of America. 2021. IDSA guidelines on the treatment and management of patients with COVID-19. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management."},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1177\/2168479017694850"},{"key":"CIT0046","unstructured":"Joffe, S., and H. F. Lynch. 2020. The FDA should not rush a COVID-19 vaccine. Washington Post, June 2, 2020. https:\/\/www.washingtonpost.com\/opinions\/2020\/06\/02\/fda-should-not-rush-covid-19-vaccine\/."},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.12867"},{"key":"CIT0048","unstructured":"Johnson, M. 2020. The young die as well from COVID-19, even as many engage in denial. Milwaukee Journal Sentinel, November 25, 2020. https:\/\/www.jsonline.com\/story\/news\/2020\/11\/25\/fighting-dangerous-myth-covid-only-threatens-old-ill\/6389206002\/."},{"key":"CIT0049","unstructured":"Joseph, A. 2020. Alzheimer\u2019s group sees signs of progress against a grim disease. Is it real? STAT, February 24, 2020. https:\/\/www.statnews.com\/2020\/02\/24\/after-40-years-the-alzheimers-association-sees-signs-of-progress-against-a-devastating-disease-is-it-real\/."},{"key":"CIT0050","unstructured":"Joyner, M. J., and A. Casadevall. 2021. Early testing of convalescent plasma: \u2018Building the plane while flying it.\u2019 STAT, March 4, 2021. https:\/\/www.statnews.com\/2021\/03\/04\/for-early-testing-of-convalescent-plasma-we-were-building-the-plane-while-we-were-flying-it\/."},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4742"},{"key":"CIT0052","unstructured":"Karlin-Smith, S. 2021a. Lagging COVID antibody uptake continues to worry US government. Pink Sheet, January 15, 2021. https:\/\/pink.pharmaintelligence.informa.com\/PS143610\/Lagging-COVID-Antibody-Uptake-Continues-To-Worry-US-Government."},{"key":"CIT0053","unstructured":"Karlin-Smith, S. 2021b. Pandemic perspectives: How COVID emergency use authorizations could reshape US FDA. Pink Sheet, April 1, 2021. https:\/\/pink.pharmaintelligence.informa.com\/PS144054\/Pandemic-Perspectives-How-COVID-Emergency-Use-Authorizations-Could-Reshape-US-FDA."},{"key":"CIT0054","unstructured":"Koh, H. 2020. Decision on convalescent plasma for COVID-19 raises questions. https:\/\/www.hsph.harvard.edu\/news\/features\/decision-on-convalescent-plasma-for-covid-19-raises-questions\/."},{"key":"CIT0055","unstructured":"Kolata, G. 2021. Kati Kariko helped shield the world from the coronavirus. New York Times, April 8, 2021. https:\/\/www.nytimes.com\/2021\/04\/08\/health\/coronavirus-mrna-kariko.html."},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7023"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1731"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1177\/1073110520935352"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-018-05719-4"},{"key":"CIT0060","unstructured":"Mayo clinic convalescent plasma COVID-19 expanded access program. n.d. https:\/\/www.uscovidplasma.org\/."},{"key":"CIT0061","unstructured":"McGinley, L. 2020. Only one Covid-19 treatment is designed to keep people out of the hospital. Many overburdened hospitals are not offering it. Washington Post, December 31, 2020. https:\/\/www.washingtonpost.com\/health\/2020\/12\/31\/covid-monoclonal-antibodies-unused\/."},{"key":"CIT0062","unstructured":"McKinsey & Company. 2021. Fast-forward: Will the speed of COVID-19 vaccine development reset industry norms? https:\/\/www.mckinsey.com\/industries\/pharmaceuticals-and-medical-products\/our-insights\/fast-forward-will-the-speed-of-covid-19-vaccine-development-reset-industry-norms."},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1177\/1740774520988669"},{"key":"CIT0064","unstructured":"Michigan Medicine. 2018. Desperately ill patients will get better access to experimental treatments through new effort. July 26, 2018. https:\/\/www.uofmhealth.org\/news\/archive\/201807\/desperately-ill-patients-will-get-better-access-experimental."},{"key":"CIT0065","unstructured":"Might, M. 2021. Scientific, moral imperatives underlie including rare disorders in the ARPA-H mandate. STAT, August 18, 2021. https:\/\/www.statnews.com\/2021\/08\/18\/arpa-h-mandate-include-rare-disorders\/"},{"key":"CIT0066","unstructured":"Murray, S. 2020. Trump gives \u2018operation warp speed\u2019 blank check to develop vaccine, source says. CNN Politics, May 1, 2020. https:\/\/www.cnn.com\/2020\/05\/01\/politics\/donald-trump-vaccine-operation-warp-speed\/index.html."},{"key":"CIT0067","unstructured":"National Cancer Institute. 2018. NCI-MATCH: More labs, new arms, initial findings. November 15, 2018. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/nci-match-update-new-arms-more-labs."},{"key":"CIT0068","unstructured":"National Institutes of Health. 2020. Overview: Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV). https:\/\/www.nih.gov\/research-training\/medical-research-initiatives\/activ."},{"key":"CIT0069","unstructured":"Neergaard, L. 2020. Years of research laid groundwork for speedy COVID-19 vaccines. PBS NewsHour, December 7, 2020. https:\/\/www.pbs.org\/newshour\/health\/years-of-research-laid-groundwork-for-speedy-covid-19-vaccines."},{"key":"CIT0070","unstructured":"NIH COVID-19 Treatment Guidelines Panel. 2021a. Anti-SARS-CoV-2 antibody products. COVID-19 treatment guidelines. https:\/\/www.covid19treatmentguidelines.nih.gov\/anti-sars-cov-2-antibody-products\/."},{"key":"CIT0071","unstructured":"NIH COVID-19 Treatment Guidelines Panel. 2021b. Therapeutic management of adults with COVID-19. https:\/\/www.covid19treatmentguidelines.nih.gov\/therapeutic-management\/."},{"key":"CIT0072","unstructured":"NIH COVID-19 Treatment Guidelines Panel. 2021c. Convalescent plasma. https:\/\/www.covid19treatmentguidelines.nih.gov\/anti-sars-cov-2-antibody-products\/convalescent-plasma\/."},{"issue":"17","key":"CIT0073","first-page":"S380","volume":"24","author":"Owens G. M.","year":"2018","journal-title":"The American Journal of Managed Care"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.10.007"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30542-8"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60137-9"},{"key":"CIT0077","unstructured":"Prasad, V. 2020. Tweet. @VPrasadMDMPH, December 27, 2020. https:\/\/twitter.com\/VPrasadMDMPH\/status\/1343249598249254912."},{"key":"CIT0078","unstructured":"Rau, N. 2020. Tennessee families impacted by ALS become advocates for congressional action. Tennessee Lookout, December 16, 2020. https:\/\/tennesseelookout.com\/2020\/12\/16\/tennessee-families-impacted-by-als-become-advocates-for-congressional-action\/."},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003564"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.25053"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.11.025"},{"key":"CIT0082","unstructured":"Rodriguez, A. 2021. Monoclonal antibodies for COVID in full supply, but lack demand: HHS. USA Today, January 14, 2021. https:\/\/www.usatoday.com\/story\/news\/health\/2021\/01\/14\/monoclonal-antibodies-covid-full-supply-but-lack-demand-hhs\/4159950001\/."},{"key":"CIT0083","unstructured":"Rogers, A. 2020. The strange and twisted tale of hydroxychloroquine. Wired, November 11, 2020. https:\/\/www.wired.com\/story\/hydroxychloroquine-covid-19-strange-twisted-tale\/."},{"key":"CIT0084","unstructured":"Rogers, A. 2021. The drug trial that could actually produce Covid treatments. Wired, May 24, 2021. https:\/\/www.wired.com\/story\/the-drug-trial-that-could-actually-produce-covid-treatments."},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2009457"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"CIT0087","doi-asserted-by":"publisher","DOI":"10.7326\/M20-5041"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000002259"},{"key":"CIT0089","unstructured":"Silverman, E. 2021. Biogen to expand access to ALS drug, but move may be too late for some. STAT, April 27, 2021. https:\/\/www.statnews.com\/pharmalot\/2021\/04\/27\/biogen-als-expanded-access-compassionate-use\/."},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2027405"},{"key":"CIT0091","unstructured":"Stahl, S. 2021. Cancer moonshot project launched by president Biden 5 years ago leading to many breakthroughs. January 21, 2021. https:\/\/philadelphia.cbslocal.com\/2021\/01\/21\/cancer-moonshot-project-launched-by-president-biden-5-years-ago-leading-to-many-breakthroughs\/."},{"key":"CIT0092","unstructured":"Tesi, R. J. 2019. It\u2019s time to take a new tack for treating Alzheimer\u2019s. STAT, April 30, 2019. https:\/\/www.statnews.com\/2019\/04\/30\/amyloid-failures-new-tack-treating-alzheimers\/."},{"key":"CIT0093","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1077-z"},{"key":"CIT0094","unstructured":"Topol, E. 2021. Eric Topol on the pandemic year: The hyper-acceleration of the life sciences. Wall Street Journal, March 19, 2021. https:\/\/www.wsj.com\/articles\/eric-topol-on-the-pandemic-year-the-hyper-acceleration-of-the-life-sciences-11616165818."},{"key":"CIT0095","unstructured":"Tsai, J. 2021. The future of pandemic preparedness: Agile coordination around clinical trials. STAT, June 10, 2021. https:\/\/www.statnews.com\/2021\/06\/10\/pandemic-preparedness-agile-coordination-clinical-trials\/."},{"key":"CIT0096","unstructured":"U.S. Food and Drug Administration. 2015. Subpart I\u2013expanded access to investigational drugs for treatment use. 21 CFR 312."},{"key":"CIT0097","unstructured":"U.S. Food and Drug Administration. 2017a. Emergency use authorization of medical products and related authorities\u2013guidance for industry and other stakeholders. https:\/\/www.fda.gov\/media\/97321\/download."},{"key":"CIT0098","unstructured":"U.S. Food and Drug Administration. 2017b. Guidance for industry: expanded access to investigational drugs for treatment use\u2014questions and answers. https:\/\/www.fda.gov\/media\/85675\/download."},{"key":"CIT0101","unstructured":"U.S. Food and Drug Administration. 2018a. Fast track, breakthrough therapy, accelerated approval, priority review. https:\/\/www.fda.gov\/patients\/learn-about-drug-and-device-approvals\/fast-track-breakthrough-therapy-accelerated-approval-priority-review."},{"key":"CIT0099","unstructured":"U.S. Food and Drug Administration. 2018b. Expanded access program report: Summary of independent assessment. https:\/\/www.fda.gov\/downloads\/AboutFDA\/ReportsManualsForms\/Reports\/UCM618903.pdf."},{"key":"CIT0102","unstructured":"U.S. Food and Drug Administration. 2018c. Master protocols: Efficient clinical trial design strategies to expedite development of oncology drugs and biologics. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/master-protocols-efficient-clinical-trial-design-strategies-expedite-development-oncology-drugs-and."},{"key":"CIT0100","unstructured":"U.S. Food and Drug Administration. 2018d. Accelerated approval. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval."},{"key":"CIT0103","unstructured":"U.S. Food and Drug Administration. 2019. Amyotrophic lateral sclerosis: Developing drugs for treatment\u2013guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/amyotrophic-lateral-sclerosis-developing-drugs-treatment-guidance-industry."},{"key":"CIT0111","unstructured":"U.S. Food and Drug Administration. 2020a. Complex innovative trial designs pilot program. https:\/\/www.fda.gov\/drugs\/development-resources\/complex-innovative-trial-designs-pilot-program."},{"key":"CIT0104","unstructured":"U.S. Food and Drug Administration. 2020b. Project facilitate. January 23, 2020. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-facilitate."},{"key":"CIT0109","unstructured":"U.S. Food and Drug Administration. 2020c. Real-world evidence. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence."},{"key":"CIT0110","unstructured":"U.S. Food and Drug Administration. 2020d. Remdesivir (Veklury) approval for the treatment of COVID-19\u2014the evidence for safety and efficacy. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/remdesivir-veklury-approval-treatment-covid-19-evidence-safety-and-efficacy."},{"key":"CIT0112","unstructured":"U.S. Food and Drug Administration. 2020e. Emergency use authorization for COVID-19 convalescent plasma. https:\/\/www.fda.gov\/media\/141477\/download."},{"key":"CIT0107","unstructured":"U.S. Food and Drug Administration. 2020f. EUA for baricitinib in combination with remdesivir. https:\/\/www.fda.gov\/media\/143822\/download."},{"key":"CIT0108","unstructured":"U.S. Food and Drug Administration. 2020g. EUA for casirivimab and imdevimab. https:\/\/www.fda.gov\/media\/143891\/download."},{"key":"CIT0105","unstructured":"U.S. Food and Drug Administration. 2020h. Emergency use authorization (revoked) for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 coronavirus disease. https:\/\/www.fda.gov\/media\/136534\/download."},{"key":"CIT0106","unstructured":"U.S. Food and Drug Administration. 2020i. Revocation of the emergency use authorization for oral formulations of chloroquine phosphate and hydroxychloroquine sulfate, https:\/\/www.fda.gov\/media\/138945\/download."},{"key":"CIT0114","unstructured":"U.S. Food and Drug Administration. 2021a. Coronavirus treatment acceleration program (CTAP). https:\/\/www.fda.gov\/drugs\/coronavirus-covid-19-drugs\/coronavirus-treatment-acceleration-program-ctap."},{"key":"CIT0113","unstructured":"U.S. Food and Drug Administration. 2021b. Conduct of clinical trials of medical products during the COVID-19 public health emergency\u2013guidance for industry, investigators, and institutional review boards. https:\/\/www.fda.gov\/media\/136238\/download."},{"key":"CIT0121","unstructured":"U.S. Food and Drug Administration. 2021c. Guidance for industry: COVID-19 master protocols evaluating drugs and biological products for treatment or prevention. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/covid-19-master-protocols-evaluating-drugs-and-biological-products-treatment-or-prevention."},{"key":"CIT0125","unstructured":"U.S. Food and Drug Administration. 2021d. Emergency use authorization, COVID-19 EUAs. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization."},{"key":"CIT0116","unstructured":"U.S. Food and Drug Administration. 2021e. EUA for bamlanivimab and etesevimab. https:\/\/www.fda.gov\/media\/145801\/download."},{"key":"CIT0122","unstructured":"U.S. Food and Drug Administration. 2021f. Emergency use authorization for sotrovimab. https:\/\/www.fda.gov\/media\/149532\/download."},{"key":"CIT0123","unstructured":"U.S. Food and Drug Administration. 2021g. Emergency use authorization for tociluzimab. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19."},{"key":"CIT0119","unstructured":"U.S. Food and Drug Administration. 2021h. COVID-19 vaccines. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines."},{"key":"CIT0124","unstructured":"U.S. Food and Drug Administration. 2021i. Emergency use authorization for REGEN-COV for post-exposure prophylaxis. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19."},{"key":"CIT0120","unstructured":"U.S. Food and Drug Administration. 2021j. Emergency use authorization. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization."},{"key":"CIT0117","unstructured":"U.S. Food and Drug Administration. 2021k. Emergency use authorization\u2013archived information. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization-archived-information."},{"key":"CIT0115","unstructured":"U.S. Food and Drug Administration. 2021l. Frequently asked questions for Veklury (Remdesivir). https:\/\/www.fda.gov\/media\/137574\/download."},{"key":"CIT0118","unstructured":"U.S. Food and Drug Administration. 2021m. Emergency use authorization for vaccines to prevent COVID-19\u2013guidance for industry. https:\/\/www.fda.gov\/media\/142749\/download."},{"key":"CIT0126","unstructured":"UsAgainstAlzheimer\u2019s. 2021. Statement on donanemab. https:\/\/www.usagainstalzheimers.org\/press\/usagainstalzheimers-statement-donanemab."},{"key":"CIT0127","unstructured":"Waters, H., and M. Graf. 2018. The costs of chronic disease in the U.S. Milken Institute. https:\/\/milkeninstitute.org\/reports\/costs-chronic-disease-us."},{"key":"CIT0128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2033538"},{"key":"CIT0129","unstructured":"World Health Organization. 2020. WHO recommends against the use of remdesivir in COVID-19 patients. November 20, 2020. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients."},{"key":"CIT0130","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3767-09.2009"},{"key":"CIT0131","unstructured":"Zimmer, C. 2021. How the search for Covid-19 treatments faltered while vaccines sped ahead. The New York Times, January 30, 2021. https:\/\/www.nytimes.com\/2021\/01\/30\/health\/covid-drugs-antivirals.html."}],"container-title":["The American Journal of Bioethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15265161.2021.1974975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T15:36:27Z","timestamp":1638372987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15265161.2021.1974975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":131,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,2]]}},"alternative-id":["10.1080\/15265161.2021.1974975"],"URL":"https:\/\/doi.org\/10.1080\/15265161.2021.1974975","relation":{},"ISSN":["1526-5161","1536-0075"],"issn-type":[{"value":"1526-5161","type":"print"},{"value":"1536-0075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=uajb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=uajb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}